Webcast Alert: Aastrom Biosciences Announces Its First Quarter Investor Conference Call
04 November 2006 - 1:00AM
Business Wire
Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following
Webcast: What: Aastrom Biosciences, Inc. First Quarter Fiscal Year
2007 Investor Conference Call When: Thursday, November 9, 2006 @
11:00 am (EST) Where: http://www.vcall.com/IC/CEPage.asp?ID=109389
How: � For live Internet access, simply log on to the web at the
address above. � For phone access, interested parties should call
toll-free (877) 407-9205 before the start of the call to register
and identify themselves as registrants of the �Aastrom Conference
Call�. Any registered caller on the toll-free line may ask for call
operator for directions to be placed in the queue for the Question
& Answer session. If calling from outside the U.S., please use
the international phone number (201) 689-8054. � To download the
podcast, simply log on to the web at the address above. Contact:
Kris Maly, Investor Relations Department, (734) 930-5777 or
mail@aastrom.com If you are unable to participate during the live
call, the webcast will be available for replay at
http://www.investorcalendar.com/ for 60 days. Also, through
November 19, 2006, the audio replay of the call�will be available
by dialing toll-free�(877) 660-6853, or from outside the U.S. (201)
612-7415. When prompted, the Account # is: 286, and the Conference
ID# is: 215272. Aastrom Biosciences, Inc. (NASDAQ: ASTM) is
developing autologous cell products for the repair or regeneration
of multiple human tissues, based on its proprietary Tissue Repair
Cell (TRC) technology. Aastrom's TRC-based products are a unique
cell mixture containing stromal, stem and progenitor cell
populations, produced outside the body from a small amount of bone
marrow taken from the patient. TRC-based products have been used in
over 230 patients, and are currently in clinical trials for bone
regeneration (long bone fractures and spine fusion) and vascular
regeneration (critical limb ischemia) applications. The Company has
reported positive interim clinical trial results for TRCs
suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration for use in the treatment of osteonecrosis of the
femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom�s website at www.aastrom.com. Aastrom Biosciences,
Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom
Biosciences, Inc. First Quarter Fiscal Year 2007 Investor
Conference Call When: Thursday, November 9, 2006 @ 11:00 am (EST)
Where: http://www.vcall.com/IC/CEPage.asp?ID=109389 How: -- For
live Internet access, simply log on to the web at the address
above. -- For phone access, interested parties should call
toll-free (877) 407-9205 before the start of the call to register
and identify themselves as registrants of the "Aastrom Conference
Call". Any registered caller on the toll-free line may ask for call
operator for directions to be placed in the queue for the Question
& Answer session. If calling from outside the U.S., please use
the international phone number (201) 689-8054. -- To download the
podcast, simply log on to the web at the address above. Contact:
Kris Maly, Investor Relations Department, (734) 930-5777 or
mail@aastrom.com If you are unable to participate during the live
call, the webcast will be available for replay at
http://www.investorcalendar.com/ for 60 days. Also, through
November 19, 2006, the audio replay of the call will be available
by dialing toll-free (877) 660-6853, or from outside the U.S. (201)
612-7415. When prompted, the Account # is: 286, and the Conference
ID# is: 215272. Aastrom Biosciences, Inc. (NASDAQ: ASTM) is
developing autologous cell products for the repair or regeneration
of multiple human tissues, based on its proprietary Tissue Repair
Cell (TRC) technology. Aastrom's TRC-based products are a unique
cell mixture containing stromal, stem and progenitor cell
populations, produced outside the body from a small amount of bone
marrow taken from the patient. TRC-based products have been used in
over 230 patients, and are currently in clinical trials for bone
regeneration (long bone fractures and spine fusion) and vascular
regeneration (critical limb ischemia) applications. The Company has
reported positive interim clinical trial results for TRCs
suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration for use in the treatment of osteonecrosis of the
femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom's website at www.aastrom.com.
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024